NDA 215211 · Amicus Therap US
Opfolda
Miglustat · Oral · Glucosylceramide Synthase Inhibitor; Enzyme Stabilizer
Breakthrough therapyOrphanLast checked: Nov 19, 2026Latest source record: Jul 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Sep 28, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30
10 Phase 3, 2 recruiting
FAERS reports
264
186 serious, 30 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 27, 2024.
OPFOLDA is indicated, in combination with Pombiliti, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). OPFOLDA is an enzyme stabilizer indicated, in combination with Pombiliti, a hydrolytic lysosomal glycogen-specific enzyme, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). ( 1 )
Mechanism: Miglustat binds with, stabilizes, and reduces inactivation of cipaglucosidase alfa-atga in the blood after infusion. The bound miglustat is dissociated from cipaglucosidase alfa-atga after it is internalized and transported into lysosomes. Miglustat alone has no pharmacological activity in cleaving glycogen.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 28, 2023 Original approval · Type 5 - New Formulation or New Manufacturer Breakthrough therapyOrphanLabelLetterReview
1 products under this application
- OPFOLDA · MIGLUSTAT 65MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Miglustat" as an intervention, any sponsor and status, largest first.
- A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT03729362 · 125 participants · Start Dec 4, 2018 · Primary completion Dec 15, 2020
Drug: Cipaglucosidase Alfa; Miglustat and 2 more · For: Pompe Disease (Late-onset)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Irvine, California · 73 sites in all
G D SearleIndustry
NCT00001993 · 120 participants
Drug: Butyldeoxynojirimycin; Zidovudine · For: HIV Infections
Sites: Miami, Florida; Chicago, Illinois; Indianapolis, Indiana · 6 sites in all
- A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)Pivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT04138277 · 119 participants · Start Dec 18, 2019 · Primary completion Dec 31, 2024
Drug: AT2221; ATB200 · For: Pompe Disease (Late-onset)
Sites: Little Rock, Arkansas; Irvine, California; Gainesville, Florida · 60 sites in all
G D SearleIndustry
NCT00000692 · 48 participants
Drug: Butyldeoxynojirimycin · For: HIV Infections
Sites: San Diego, California; Stanford, California; Miami, Florida · 6 sites in all
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT01822028 · 42 participants · Start Mar 2013 · Primary completion Jun 2013
Drug: Treatment A; Treatment B · For: Diarrhea
Sites: Toronto, Canada
- Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher DiseasePivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00319046 · 42 participants · Start Feb 1, 2006 · Primary completion Jun 1, 2010
Drug: Miglustat · For: Gaucher Disease Type 1
- A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18Pivotal-lookingRecruiting
Amicus TherapeuticsIndustry
NCT04808505 · 36 participants (planned) · Start Jul 18, 2023 · Primary completion Jul 2027
Drug: Cipaglucosidase alfa; Miglustat · For: Glycogen Storage Disease Type II Infantile Onset
Sites: Gainesville, Florida; Atlanta, Georgia; Durham, North Carolina · 14 sites in all
National Institute of Neurological Disorders and Stroke (NINDS)NIH
NCT00041535 · 30 participants · Start Jul 5, 2002
Drug: OGT 918 · For: Gaucher Disease
Sites: Bethesda, Maryland; London, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pneumonia24
- seizure24
- diarrhoea20
- vomiting15
- off label use14
- nausea12
- pyrexia12
- asthenia11
- condition aggravated11
- fatigue11
- respiratory failure11
- weight decreased11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 3 |
| 2017 | 1 |
| 2018 | 10 |
| 2019 | 12 |
| 2020 | 11 |
| 2021 | 16 |
| 2022 | 18 |
| 2023 | 21 |
| 2024 | 51 |
| 2025 | 64 |
| 2026 | 48 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Opfolda (Miglustat)
2024 spending
$41K
Beneficiaries
22
163 claims
Per beneficiary
$1,844
$33.47 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $40,568 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B, Roberts M, Byrne BJ, et al. · Lancet Neurol 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment.
Mengel E, Patterson MC, Da Riol RM, et al. · J Inherit Metab Dis 2021 · Clinical Trial, Phase II, Clinical Trial, Phase III
- 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Schoser B, Kishnani PS, Bratkovic D, et al. · J Neurol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of efavirenz in Niemann-Pick disease type C.
Gascón-Bayarri J, Rico I, Sánchez-Castañeda C, et al. · Neurotherapeutics 2025 · Clinical Trial, Phase II
- Efficacy and safety of miglustat in the treatment of GM2 gangliosidosis: A systematic review.
Mansouri V, Tavasoli AR, Khodarahmi M, et al. · Eur J Neurol 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.
Kishnani PS, Byrne BJ, Claeys KG, et al. · J Patient Rep Outcomes 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Amicus Therap US
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.